Loading company details…
Draupnir Bio ApS develops small‑molecule therapeutics that target PCSK9 and related pathways, aiming Sign up to read more
Profile updated Jun 2026
No share issues or funding rounds.
Companies with the most similar business descriptions.
No accounts data available
These are the directors and secretaries who have left DRAUPNIR BIO APS. A resignation is filed with Companies House on form TM01 and the date below is the date the officer's appointment ended, not the date it was filed. Departures matter for reading a company's history: a founder leaving shortly after a funding round, or several directors resigning at once, is often the visible trace of a change of control or a restructure.